Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Medtronic
Express Scripts
Dow

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Patent: 9,670,202

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,670,202
Title:Substituted triazolopyridines
Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds. ##STR00001##
Inventor(s): Schirok; Hartmut (Langenfeld, DE), Schulze; Volker (OT Bergf, DE), Kosemund; Dirk (Berlin, DE), Briem; Hans (Berlin, DE), Bader; Benjamin (Berlin, DE), Bomer; Ulf (Glienicke, DE), Wengner; Antje Margret (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Lienau; Philip (Berlin, DE)
Assignee: BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)
Application Number:14/896,426
Patent Claims:see list of patent claims

Details for Patent 9,670,202

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2033-06-07 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2033-06-07 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2033-06-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Merck
Medtronic
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.